Mfg. of : Bulk Drugs, Drug Intermediates & Speciality Chemicals



Date: 12th August, 2022

To, Listing Department, BSE Limited, Floor 25, PJ Tower Dalal Street, Mumbai – 400 001 Script Code: 540359

Sub.: Outcome of the meeting of the Board of Directors of the Company

Dear Sirs,

In continuation of our Corporate announcement dated 4th August, 2022 we hereby inform you that the Board of Directors of the Company has, at its meeting held today, inter—alia, considered and approved the Unaudited Financial Results for quarter ended 30th June, 2022. The same has also been reviewed by the Audit Committee in its meeting held today.

A copy of the Statement of Unaudited Financial Results for the quarter ended 30th June, 2022. Further we are submitting the Limited Review report on Unaudited Financial Results for quarter ended 30th June, 2022 issued by our Statutory Auditors.

The meeting was concluded at 7:40 pm.

Kindly take this on your records.

Thanking you,

Yours faithfully,

For, Parmax Pharma Limited

Yash Vora Company Secretary

Encl: As above

PARMAX PHARMA LIMITED

Regd. Off. & Factory: Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot-360 311, Gujarat, INDIA. Tel.: Fac.+91-2827-270534 - 35 - 36 e-mail: info@parmaxpharma.com CIN: L24231GJ1994PLC023504



Mfg. of : Bulk Drugs, Drug Intermediates & Speciality Chemicals

Statement of Standalone Unaudited Results for the Quarter ended 30.06.2022					
	1	T			(in Rs.
Sr.	Particulars	Quarter Ended	Preceeding	Corresponding	Previous year
		(30.06.2022)	Quarter ended	Quarter Ended	ended
No.			(31.03.2022)	(30.06.2021)	(31.03.2022)
_	(Refer Notes Below)	(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Income from Operations				
	(a) Revenue from operations	15553554	70879782	17348202	182511198
	(b) Other income	84004	167997	157580	62780
	Total income from operations (net) (a+b)	15637558	71047779	17505782	183139005
2	Expenses	10007000	11041113	17505782	18515500.
3	(a) Cost of materials consumed	12801908	37652713	8110278	67179404
	(b) Purchase of stock-in-trade	0	0	0	(
	(c) Changes in inventories of finished goods, work-in-				
	progress and stock-in-trade	-7995621	-93629	-9261958	-61000
	(d) Employee benefits expense	5481057	4841382	8118977	34616065
	(e) Finance Costs	914050	854887	933464	3858120
	(f) Depreciation and amortisation expense	4614079	4993803	4709329	19320893
	(g) Other expenses*	13002973	21640705	9246562	55192824
	Total expenses	28818446	69889860	21856652	180106306
	Profit/(Loss) from operations before exceptional items				
	and tax (1-2)	-13180888	1157919	-4350870	3032700
	Exceptional Items	0	0	0	(
	Profit/ (Loss) before tax (3-4)	-13180888	1157919	-4350870	3032700
5	Tax expense:				
	(1) Current tax	0	2250000	0	2250000
	(2) Deferred tax	0	632434	0	632434
	Net Profit / (Loss) for the period from continuing	-13180888	-459647	-4350870	1415124
	operations (5-6)	-13180888	-439047	-4350870	1415134
	Profit/(loss) from discontinuing operations	0		0	
	Tax expense of discontinuing operations	0	0	0	0
0	Profit/(loss) from Discontinuing operations (after tax) (8-9)	0	0	0	0
1	Profit (Loss) for the period (7+10)	-13180888	-459647	-4350870	1415134
2	Other Comprehensive Income	0	0	0	0
	Total Comprehensive Income for the period (11+12)				
	Comprising Profit (Loss) and Other comprehensive Income	-13180888	-459647	-4350870	1415134
	for the period)				
4	Paid-up equity share capital (Face Value Rs 10)	37413000	37413000	37413000	37413000
.5	Earnings per share (for continuing operation)				
	(of Rs. 10/- each) (not annualised):				
	(a) Basic	-3.52	-0.12	-1.16	0.38
	(b) Diluted	-			



PARMAX PHARMA LIMITED

Regd. Off. & Factory : Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot-360 311, Gujarat, INDIA. Tel.: Fac.+91-2827-270534 - 35 - 36 e-mail : info@parmaxpharma.com CIN : L24231GJ1994PLC023504

Correspondence Add.: A/1102, Bilipatra Apts., B/h. Balaji Hall, Nr. Dholakiya School, Off. 150 Ft. Ring Road, Nana Mauva, Rajkot - 360 004, Gujarat (INDIA)



Notes:

1. The above unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held or: 12th August, 2022.

2. The stautory Auditors have carried out a Limited Review of the Unaudited standalone results of the quarter ended 30th June, 2022.

3. The Company is operating in single (pharmaceutical) segment, see above results are for single segment only.

4. Steament of Unaudited Financial Results of the company for the quarter ended 30th June, 2022 in the prescribed format under Schedule III of . . mpanies Act, 2013

5. The sources for the previous period have been regrouped where ver necessary.

* The Company has decided to gradually write off its all Preliminary and Pre-oprative expenses which are forming the part of Balance Sheet accordingly Company has writen off Rs. 9,90,350/- during this quarter under review and it is forming part of Other Expenses.

OF, PARMAX PHARMA LIMITED

Zosalez

D Umang Alkesh Gosalia **Managing Director**



Place, Fudamtala (Rajkot) Date: 12.08.2022

PARMAX PHARMA LIMITED

Regd. Off. & Factory : Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot-360 311, Gujarat, INDIA. Tel.: Fac.+91-2827-270534 - 35 - 36 e-mail : info@parmaxpharma.com CIN : L24231GJ1994PLC023504

Correspondence Add.: A/1102, Bilipatra Apts., B/h. Balaji Hall, Nr. Dholakiya School, Off. 150 Ft. Ring Road, Nana Mauva, Rajkot - 360 004, Gujarat (INDIA)

B A SHAH S R MEHTA & Co. Chartered Accountants

Partner Malay B Shah B.Com. F.C.A. M. No. 159526 Partner Zarna M Shah M.Com. F.C.A. DISA (Information Systems Audit) M. No. 144246

Auditor's Limited Review Report On Unaudited Financial Results

To

The Board of Directors, PARMAX PHARMA LIMITED

We have reviewed the accompanying statement of standalone unaudited financial results of **PARMAX PHARMA LTD** ("the Company") for the quarter and three months ended **30th June 2022** ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This Statement is the responsibility of the Company's management and has been approved by the Board of Directors on **12th August 2022**. Our responsibility is to issue a report on this Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial date thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of standalone unaudited financial results prepared in accordance with applicable accounting standards i.e. Indian Accounting Standards (IND AS) prescribed under Section 133 of the Companiant, 2013, read with collevant cules issued there



Electronic Address: (0) 0281-2468261

Head Office: 209-Sapphire Complex, IInd Floor 21/25-B New Jagnath Plot, Dr.Yagnik Road Branch Office: 302-Vede & Complex, 7/B K 19 Society, C.G.Roac, sevrangpura, AHMEDABAD = 380,009

(M) 09427564149

(E) baccrmco office@amail

BASHAHSR MEHTA & Co. Chartered Accountants

Partner Malay B Shah B.Com. F.C.A. M. No. 159526

Partner Zarna M Shah M.Com. F.C.A. DISA (Information Systems Audit) M. No. 144246

under and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SE 21 (Lating Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For

Place : Rajkot Date : 12.08.2022



B. A. SHAH S R MEHTA & Co. Chartered Accountants FRN NO : 128796W

MALAY B SHAH Partner M. No. 159526 UDIN: 22159526AOXXJX6863

Head Office: 209-Sapphire Complex, IInd Floor 21/25-B New Jagnath Plot, Dr.Yagnik Road <u>RAJKOT- 360 001</u>

<u>Br</u><u>Office:</u> 302-Veda t Complex, 7/B Kalpana Society, C.G.Road, Navrangpura, AHMEDAB/ D = 380,009

Electronic Address: (0) 0281-2468261

(M) 09427564149